{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:49Z","timestamp":1791357349214,"version":"4.3.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/nmd.0000000000000069","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T08:13:13Z","timestamp":1388131993000},"page":"13-17","source":"Crossref","is-referenced-by-count":15,"title":["Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia"],"prefix":"10.1097","volume":"202","author":[{"given":"Sarah M.","family":"Leatherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Valley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soe Soe","family":"Thwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210208","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotics for people with schizophrenia.","volume":"179","author":"Adams","year":"2001","journal-title":"Br J Psychiatry"},{"key":"R2-4-20210208","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4088\/JCP.v68n0808","article-title":"Equivalent switching dose from oral risperidone to risperidone long-acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study.","volume":"68","author":"Bai","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R4-4-20210208","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","article-title":"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.","volume":"15","author":"Chue","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R5-4-20210208","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-4-20210208","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","article-title":"Depot antipsychotic drugs: Place in therapy.","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"R8-4-20210208","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial.","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R9-4-20210208","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: An instrument for rating the schizophrenic deficit syndrome.","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"key":"R10-4-20210208","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","article-title":"Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.","volume":"36","author":"Hogarty","year":"1979","journal-title":"Arch Gen Psychiatry"},{"key":"R11-4-20210208","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic.","volume":"160","author":"Kane","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R12-4-20210208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive And Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R13-4-20210208","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1176\/appi.ps.55.9.997","article-title":"Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.","volume":"55","author":"Keith","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R14-4-20210208","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.","volume":"191","author":"Keks","year":"2007","journal-title":"Br J Psychiatry"},{"key":"R15-4-20210208","first-page":"23","article-title":"A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia.","volume":"7","author":"Macfadden","year":"2010","journal-title":"Psychiatry"},{"key":"R17-4-20210208","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R18-4-20210208","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.","volume":"168","author":"McLellan","year":"1980","journal-title":"J Nerv Ment Dis"},{"key":"R19-4-20210208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08039480510018832","article-title":"Therapeutic drug monitoring of patients on risperidone depot.","volume":"59","author":"Nesvag","year":"2005","journal-title":"Nord J Psychiatry"},{"key":"R21-4-20210208","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1176\/appi.ps.54.4.508","article-title":"An economic review of compliance with medication in the treatment of schizophrenia.","volume":"54","author":"Thieda","year":"2003","journal-title":"Psychiatr Serv"},{"key":"R22-4-20210208","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/21.3.419","article-title":"Cost of relapse in schizophrenia.","volume":"21","author":"Weiden","year":"1995","journal-title":"Schizophr Bull"}],"container-title":["Journal of Nervous & Mental Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NMD.0000000000000069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:14:32Z","timestamp":1620965672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005053-201401000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/nmd.0000000000000069","relation":{},"ISSN":["0022-3018"],"issn-type":[{"value":"0022-3018","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}